2 1 Shi Ji Jing Ji Bao Dao·2025-06-12 10:36Core Viewpoint - The recent monopolistic practices in the raw material drug sector have led to significant penalties for several pharmaceutical companies, highlighting the ongoing issues of price manipulation and collusion in the industry [2][4][12]. Summary by Sections Monopolistic Practices and Penalties - Lianhuan Pharmaceutical was fined 61.0382 million yuan for manipulating the price of dexamethasone phosphate raw materials, which accounts for 72.53% of its projected net profit for 2024 [2][4]. - The total fines for the involved companies, including Jinyuan Pharmaceutical and Xianju Pharmaceutical, reached 326 million yuan [2]. - Dexamethasone prices surged from 0.35 yuan to 98.76 yuan per unit, a staggering increase of 282 times [4]. Nature of Collusion - The actions of Jinyuan Pharmaceutical, Lianhuan Pharmaceutical, Xianju Guokang Ruijin, and Xianju Pharmaceutical are characterized as typical price-fixing collusion, which is a form of horizontal monopoly agreement [3]. - Such collusion is often covert, making it difficult to detect externally, as only the price increases are visible [3]. Regulatory Response and Compliance - In response to the penalties, Lianhuan Pharmaceutical has initiated corrective actions, including terminating improper practices and sending price adjustment notices to clients [5]. - The penalties varied significantly among the companies, with Lianhuan receiving a 30% reduction due to cooperation during the investigation, while others received different levels of leniency based on their compliance [5][6]. Historical Context and Industry Trends - The pharmaceutical industry has seen a rise in monopolistic cases, with Jinyuan Pharmaceutical being a repeat offender, having faced multiple penalties in recent years [7]. - The raw material drug sector is particularly prone to monopolistic behavior due to its concentrated market structure, contrasting with the more competitive formulation market [7]. Evidence and Enforcement - The enforcement of antitrust laws has been strengthened, with recent cases revealing organized efforts to manipulate prices through meetings and agreements among competitors [9][11]. - The introduction of personal liability for individuals involved in monopolistic practices marks a significant shift in regulatory enforcement [10]. Future Implications - The recent penalties are expected to deter similar behaviors in the industry, promoting compliance and encouraging companies to adopt legitimate business practices [12][14]. - The evolving regulatory framework aims to address the complexities of monopolistic behavior in the pharmaceutical sector, enhancing oversight and accountability [14].